 Marta Ceko
Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chronic Pain | 11 | 2024 | 262 | 2.450 |
Why?
| | Fibromyalgia | 8 | 2021 | 52 | 1.950 |
Why?
| | Cerebral Cortex | 5 | 2020 | 433 | 1.340 |
Why?
| | Cognition | 6 | 2024 | 1153 | 1.320 |
Why?
| | Magnetic Resonance Imaging | 16 | 2024 | 3566 | 1.180 |
Why?
| | Brain Mapping | 7 | 2024 | 503 | 1.150 |
Why?
| | Pain | 6 | 2022 | 756 | 1.020 |
Why?
| | Brain | 8 | 2024 | 2668 | 1.020 |
Why?
| | Pain Measurement | 6 | 2024 | 521 | 0.910 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2024 | 59 | 0.870 |
Why?
| | Virtual Reality Exposure Therapy | 1 | 2024 | 7 | 0.870 |
Why?
| | Back Pain | 1 | 2024 | 51 | 0.840 |
Why?
| | Reading | 1 | 2024 | 135 | 0.810 |
Why?
| | Connectome | 2 | 2021 | 86 | 0.650 |
Why?
| | Healthy Volunteers | 3 | 2020 | 199 | 0.630 |
Why?
| | Neural Pathways | 5 | 2021 | 295 | 0.530 |
Why?
| | Memory, Short-Term | 2 | 2016 | 250 | 0.500 |
Why?
| | Nociception | 2 | 2024 | 16 | 0.490 |
Why?
| | Low Back Pain | 2 | 2021 | 108 | 0.450 |
Why?
| | Memory Disorders | 1 | 2015 | 164 | 0.440 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 183 | 0.440 |
Why?
| | Placebo Effect | 3 | 2024 | 25 | 0.430 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2014 | 67 | 0.420 |
Why?
| | Nerve Net | 2 | 2021 | 256 | 0.420 |
Why?
| | Benzamides | 1 | 2014 | 216 | 0.400 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 122 | 0.400 |
Why?
| | Polyradiculopathy | 1 | 2012 | 2 | 0.390 |
Why?
| | Cold Temperature | 1 | 2014 | 179 | 0.390 |
Why?
| | Prefrontal Cortex | 3 | 2024 | 301 | 0.390 |
Why?
| | Nerve Fibers | 1 | 2012 | 96 | 0.370 |
Why?
| | Analgesia | 3 | 2024 | 94 | 0.370 |
Why?
| | Piperazines | 1 | 2014 | 350 | 0.360 |
Why?
| | Hot Temperature | 1 | 2014 | 391 | 0.350 |
Why?
| | Pyrimidines | 1 | 2014 | 470 | 0.340 |
Why?
| | Pain Threshold | 3 | 2014 | 74 | 0.310 |
Why?
| | Emotions | 3 | 2021 | 548 | 0.290 |
Why?
| | Neuroimaging | 2 | 2024 | 259 | 0.290 |
Why?
| | Adult | 16 | 2024 | 37929 | 0.270 |
Why?
| | Pain Perception | 4 | 2014 | 24 | 0.260 |
Why?
| | Affect | 3 | 2024 | 292 | 0.230 |
Why?
| | Nociceptive Pain | 1 | 2024 | 4 | 0.230 |
Why?
| | Touch | 2 | 2016 | 36 | 0.230 |
Why?
| | Middle Aged | 11 | 2024 | 33479 | 0.220 |
Why?
| | Catastrophization | 1 | 2024 | 16 | 0.220 |
Why?
| | Female | 19 | 2024 | 73304 | 0.220 |
Why?
| | Humans | 27 | 2024 | 137585 | 0.220 |
Why?
| | Neurosciences | 1 | 2024 | 25 | 0.210 |
Why?
| | Young Adult | 9 | 2024 | 13209 | 0.200 |
Why?
| | Virtual Reality | 1 | 2024 | 61 | 0.200 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2129 | 0.190 |
Why?
| | Comprehension | 1 | 2024 | 172 | 0.190 |
Why?
| | Male | 15 | 2024 | 67762 | 0.190 |
Why?
| | Hypothalamus, Posterior | 1 | 2021 | 3 | 0.180 |
Why?
| | Pulvinar | 1 | 2021 | 3 | 0.180 |
Why?
| | Escape Reaction | 1 | 2021 | 62 | 0.180 |
Why?
| | Periaqueductal Gray | 1 | 2021 | 40 | 0.180 |
Why?
| | Superior Colliculi | 1 | 2021 | 40 | 0.170 |
Why?
| | Functional Neuroimaging | 1 | 2021 | 55 | 0.170 |
Why?
| | Deception | 1 | 2020 | 20 | 0.170 |
Why?
| | Amygdala | 1 | 2021 | 191 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 4 | 2018 | 752 | 0.160 |
Why?
| | Disclosure | 1 | 2020 | 113 | 0.150 |
Why?
| | Visual Analog Scale | 1 | 2018 | 33 | 0.150 |
Why?
| | Gray Matter | 2 | 2016 | 80 | 0.150 |
Why?
| | Fear | 1 | 2021 | 338 | 0.140 |
Why?
| | Behavior, Animal | 1 | 2021 | 501 | 0.140 |
Why?
| | Diffusion Tensor Imaging | 2 | 2015 | 79 | 0.140 |
Why?
| | Attitude to Health | 1 | 2020 | 439 | 0.130 |
Why?
| | Proprioception | 1 | 2016 | 26 | 0.130 |
Why?
| | Sensation Disorders | 1 | 2016 | 37 | 0.130 |
Why?
| | Central Nervous System Sensitization | 1 | 2016 | 5 | 0.120 |
Why?
| | Touch Perception | 1 | 2016 | 17 | 0.120 |
Why?
| | Ion Channels | 1 | 2016 | 133 | 0.120 |
Why?
| | Multimodal Imaging | 1 | 2016 | 113 | 0.120 |
Why?
| | Receptors, Opioid, mu | 1 | 2016 | 74 | 0.120 |
Why?
| | Gene Silencing | 1 | 2016 | 195 | 0.120 |
Why?
| | Cognitive Reserve | 1 | 2015 | 16 | 0.120 |
Why?
| | Treatment Outcome | 2 | 2024 | 10811 | 0.120 |
Why?
| | Zygapophyseal Joint | 1 | 2015 | 6 | 0.120 |
Why?
| | Pain Management | 2 | 2021 | 352 | 0.110 |
Why?
| | Rest | 1 | 2015 | 121 | 0.110 |
Why?
| | Imatinib Mesylate | 1 | 2014 | 79 | 0.110 |
Why?
| | Spine | 1 | 2015 | 173 | 0.100 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2012 | 8 | 0.100 |
Why?
| | Yoga | 1 | 2013 | 31 | 0.100 |
Why?
| | Skin | 2 | 2014 | 752 | 0.090 |
Why?
| | Neurons, Afferent | 1 | 2012 | 97 | 0.090 |
Why?
| | Cognition Disorders | 1 | 2016 | 496 | 0.090 |
Why?
| | Hyperalgesia | 1 | 2012 | 123 | 0.090 |
Why?
| | Qualitative Research | 1 | 2018 | 1386 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2020 | 3556 | 0.090 |
Why?
| | Dopamine | 1 | 2013 | 303 | 0.090 |
Why?
| | Neuronal Plasticity | 1 | 2012 | 290 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 4149 | 0.080 |
Why?
| | Surveys and Questionnaires | 3 | 2020 | 5778 | 0.080 |
Why?
| | Naloxone | 2 | 2021 | 122 | 0.070 |
Why?
| | Models, Neurological | 2 | 2021 | 242 | 0.070 |
Why?
| | Physical Stimulation | 2 | 2016 | 65 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1050 | 0.050 |
Why?
| | Analgesics | 1 | 2024 | 206 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2024 | 405 | 0.050 |
Why?
| | Oxygen | 2 | 2018 | 931 | 0.050 |
Why?
| | Cholecystokinin | 1 | 2021 | 12 | 0.050 |
Why?
| | Rats, Long-Evans | 1 | 2021 | 125 | 0.040 |
Why?
| | Aversive Agents | 1 | 2021 | 1 | 0.040 |
Why?
| | Facial Pain | 1 | 2021 | 12 | 0.040 |
Why?
| | Capsaicin | 1 | 2021 | 26 | 0.040 |
Why?
| | Video Recording | 1 | 2021 | 180 | 0.040 |
Why?
| | Photic Stimulation | 1 | 2021 | 241 | 0.040 |
Why?
| | Signal Transduction | 1 | 2014 | 5079 | 0.040 |
Why?
| | Animals | 3 | 2021 | 36940 | 0.040 |
Why?
| | Optogenetics | 1 | 2021 | 108 | 0.040 |
Why?
| | Visual Perception | 1 | 2021 | 160 | 0.040 |
Why?
| | Taste | 1 | 2021 | 229 | 0.040 |
Why?
| | Aged | 2 | 2016 | 23961 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 795 | 0.030 |
Why?
| | Adolescent | 4 | 2021 | 21513 | 0.030 |
Why?
| | Flumazenil | 1 | 2016 | 8 | 0.030 |
Why?
| | Body Water | 1 | 2016 | 21 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2018 | 186 | 0.030 |
Why?
| | Brain Chemistry | 1 | 2016 | 117 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 1431 | 0.030 |
Why?
| | Vibration | 1 | 2016 | 72 | 0.030 |
Why?
| | Vulvodynia | 1 | 2016 | 2 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2167 | 0.030 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2016 | 17 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2016 | 178 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1946 | 0.030 |
Why?
| | Irritable Bowel Syndrome | 1 | 2016 | 28 | 0.030 |
Why?
| | Receptors, GABA-A | 1 | 2016 | 142 | 0.030 |
Why?
| | Mechanotransduction, Cellular | 1 | 2016 | 111 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2031 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 2016 | 170 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2016 | 294 | 0.030 |
Why?
| | Postmenopause | 1 | 2016 | 366 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1710 | 0.030 |
Why?
| | Dopamine D2 Receptor Antagonists | 1 | 2013 | 5 | 0.030 |
Why?
| | Sulpiride | 1 | 2013 | 5 | 0.030 |
Why?
| | Thermosensing | 1 | 2013 | 12 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 611 | 0.030 |
Why?
| | Narcotic Antagonists | 1 | 2016 | 181 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 730 | 0.030 |
Why?
| | Phenylalanine | 1 | 2013 | 68 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 812 | 0.030 |
Why?
| | Receptors, Dopamine D2 | 1 | 2013 | 97 | 0.020 |
Why?
| | Tyrosine | 1 | 2013 | 222 | 0.020 |
Why?
| | Presynaptic Terminals | 1 | 2013 | 88 | 0.020 |
Why?
| | Rats | 1 | 2021 | 5647 | 0.020 |
Why?
| | Mice | 2 | 2021 | 17787 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2016 | 1023 | 0.020 |
Why?
| | White Matter | 1 | 2013 | 145 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6828 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5757 | 0.020 |
Why?
| | Attention | 1 | 2013 | 427 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2833 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 3196 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2828 | 0.020 |
Why?
| | Anxiety | 1 | 2013 | 1035 | 0.020 |
Why?
| | Child | 1 | 2016 | 21935 | 0.010 |
Why?
|
|
Ceko's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|